IL220939D0 - Compounds and methods - Google Patents
Compounds and methodsInfo
- Publication number
- IL220939D0 IL220939D0 IL220939A IL22093912A IL220939D0 IL 220939 D0 IL220939 D0 IL 220939D0 IL 220939 A IL220939 A IL 220939A IL 22093912 A IL22093912 A IL 22093912A IL 220939 D0 IL220939 D0 IL 220939D0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y02A50/411—
-
- Y02A50/463—
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29457510P true | 2010-01-13 | 2010-01-13 | |
PCT/US2011/021089 WO2011088181A1 (en) | 2010-01-13 | 2011-01-13 | Compounds and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
IL220939D0 true IL220939D0 (en) | 2012-09-24 |
IL220939A IL220939A (en) | 2016-11-30 |
Family
ID=44304635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL220939A IL220939A (en) | 2010-01-13 | 2012-07-12 | Compounds for the inhibition of hdac and pharmaceutical compositions comprising them |
Country Status (15)
Country | Link |
---|---|
US (2) | US8901156B2 (en) |
EP (1) | EP2533783B8 (en) |
JP (1) | JP6017313B2 (en) |
KR (1) | KR101781663B1 (en) |
CN (1) | CN103221047B (en) |
AU (1) | AU2011205283B2 (en) |
BR (1) | BR112012017441B1 (en) |
CA (1) | CA2787018A1 (en) |
EA (1) | EA022964B1 (en) |
ES (1) | ES2560627T3 (en) |
IL (1) | IL220939A (en) |
MX (1) | MX341133B (en) |
SG (1) | SG182401A1 (en) |
WO (1) | WO2011088181A1 (en) |
ZA (1) | ZA201205125B (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013517281A (en) | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. | Compounds and methods |
CN103764635B (en) * | 2011-07-08 | 2016-01-20 | 诺华股份有限公司 | New trifluoromethyl-oxadiazole derivative and the purposes in disease treatment thereof |
WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
WO2013066835A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
JP5966014B2 (en) * | 2011-11-28 | 2016-08-10 | ノバルティス アーゲー | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases |
US9072301B2 (en) | 2012-02-03 | 2015-07-07 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113778A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
US9055750B2 (en) | 2012-02-03 | 2015-06-16 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113787A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
NZ704666A (en) * | 2012-08-23 | 2018-05-25 | Alios Biopharma Inc | Compounds for the treatment of paramoxyvirus viral infections |
CN102826985B (en) * | 2012-09-18 | 2015-08-19 | 厦门大学 | A kind of preparation method of 1-(3,4,5-trihydroxy-) phenyl-1-alkyl ketone |
JP6423372B2 (en) | 2013-02-28 | 2018-11-14 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors |
AR094929A1 (en) | 2013-02-28 | 2015-09-09 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
CN103214327A (en) * | 2013-03-22 | 2013-07-24 | 郑州泰基鸿诺药物科技有限公司 | Aromatic ring or heteroaromatic trifluoromethyl ketone compound and preparation method thereof |
CA2921294A1 (en) * | 2013-08-21 | 2015-02-26 | Alios Biopharma, Inc. | Antiviral compounds |
WO2015057659A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
JP6483666B2 (en) | 2013-10-14 | 2019-03-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Selectively substituted quinoline compounds |
PL226024B1 (en) * | 2013-10-23 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | New application of N-[2-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]ethyl]-2-oxo-1,5,6,7-tetrahydrocyclopenta[b] pyridyno-3-carboxyamide |
CN106455572B (en) | 2014-06-06 | 2020-01-14 | 巴斯夫欧洲公司 | Use of substituted oxadiazoles for combating phytopathogenic fungi |
JP6556146B2 (en) | 2014-08-26 | 2019-08-07 | 武田薬品工業株式会社 | Heterocyclic compounds |
JP6660060B2 (en) | 2014-09-16 | 2020-03-04 | セルジーン クオンティセル リサーチ,インク. | Histone demethylase inhibitor |
US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
WO2017161033A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CN104262281A (en) * | 2014-10-16 | 2015-01-07 | 湖南华腾制药有限公司 | Preparation method of 2-bromo-4(4-ethoxyphenyl) oxazole |
WO2016065583A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Oxazole orexin receptor antagonists |
US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
EP3230281A1 (en) | 2014-12-09 | 2017-10-18 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
MX2017009950A (en) | 2015-02-02 | 2017-11-23 | Forma Therapeutics Inc | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors. |
US10799479B2 (en) | 2015-04-10 | 2020-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of DIM-related indoles |
WO2016179554A1 (en) | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
MX2017014299A (en) | 2015-05-07 | 2018-08-09 | Chdi Foundation Inc | Histone deacetylase inhibitors and compositions and methods of use thereof. |
WO2017014170A1 (en) * | 2015-07-17 | 2017-01-26 | 武田薬品工業株式会社 | Heterocyclic compound |
WO2017014321A1 (en) | 2015-07-17 | 2017-01-26 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
NZ739026A (en) | 2015-07-27 | 2019-03-29 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
MX2018001196A (en) * | 2015-07-27 | 2018-05-22 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same. |
CN107980040A (en) | 2015-07-27 | 2018-05-01 | 株式会社钟根堂 | 1,3,4- oxadiazoles sulfamide derivative as 6 inhibitor of histone deacetylase enzyme and the medical composition containing it |
EP3331864A4 (en) * | 2015-08-04 | 2019-05-01 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
JPWO2017033946A1 (en) | 2015-08-25 | 2018-06-07 | 武田薬品工業株式会社 | Heterocyclic compounds |
MX2018004038A (en) | 2015-10-02 | 2019-07-18 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives. |
WO2017055469A1 (en) | 2015-10-02 | 2017-04-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
JP6697074B2 (en) | 2015-10-12 | 2020-05-20 | チョン クン ダン ファーマシューティカル コーポレーション | Oxadiazole amine derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing the same |
EP3167716A1 (en) | 2015-11-10 | 2017-05-17 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
AR106679A1 (en) | 2015-11-13 | 2018-02-07 | Basf Se | OXADIAZOLS REPLACED TO FIGHT FITOPATHOGEN FUNGI |
BR112018009539A2 (en) | 2015-11-13 | 2018-11-06 | Basf Se | use of compounds of formula i, compounds, mixture, agrochemical composition, use of compounds and method to combat phytopathogenic harmful fungi |
BR112018008449A2 (en) | 2015-11-19 | 2018-11-06 | Basf Se | use of formula compounds, formula compounds, mixture, agrochemical composition and method to combat phytopathogenic harmful fungi |
UY36999A (en) | 2015-12-02 | 2017-06-30 | Syngenta Participations Ag | Aryl oxadiazole derivatives fungicides |
JP2019501171A (en) | 2015-12-22 | 2019-01-17 | シンジェンタ パーティシペーションズ アーゲー | Pest control active pyrazole derivative |
UY37062A (en) | 2016-01-08 | 2017-08-31 | Syngenta Participations Ag | DERIVATIVES OF ARYL OXADIAZOL FUNGICIDAS |
CN105503716A (en) * | 2016-01-30 | 2016-04-20 | 天长市淳峰精细材料合成厂 | Preparation method of 2,6-dicyanopyridine |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
WO2017222950A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
AR109304A1 (en) | 2016-08-10 | 2018-11-21 | Sumitomo Chemical Co | Oxadiazole compound and its use |
WO2018057933A1 (en) * | 2016-09-22 | 2018-03-29 | The Regents Of The University Of Colorado, A Body Corporate | Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes |
US10435399B2 (en) | 2017-07-31 | 2019-10-08 | Takeda Pharmaceutical Company Limited | HDAC6 inhibitory heterocyclic compound |
CN112351981A (en) | 2018-06-29 | 2021-02-09 | 先正达农作物保护股份公司 | Microbicidal oxadiazole derivatives |
KR20200012316A (en) * | 2018-07-26 | 2020-02-05 | 주식회사 종근당 | 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same |
WO2020032071A1 (en) * | 2018-08-08 | 2020-02-13 | 日本農薬株式会社 | Oxadiazoline compound or salt thereof, agricultural or horticultural bactericide containing said compound, and use method therefor |
CN112194620A (en) * | 2020-12-04 | 2021-01-08 | 苏州开元民生科技股份有限公司 | Preparation method of 2-ethyl-4-cyanopyridine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
EP1212357B1 (en) | 1999-09-08 | 2007-05-02 | Sloan-Kettering Institute For Cancer Research | Crystal structure of a deacetylase and inhibitors thereof |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
CA2590811C (en) * | 2004-12-10 | 2013-07-30 | Barbara Attenni | Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
US20060223837A1 (en) | 2005-03-24 | 2006-10-05 | Ellen Codd | Biaryl derived amide modulators of vanilloid VR1 receptor |
GB0603041D0 (en) * | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
JP2013517281A (en) | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. | Compounds and methods |
US20120322827A1 (en) | 2010-01-13 | 2012-12-20 | Erkan Baloglu | Compounds and methods |
WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
CN103764635B (en) | 2011-07-08 | 2016-01-20 | 诺华股份有限公司 | New trifluoromethyl-oxadiazole derivative and the purposes in disease treatment thereof |
-
2011
- 2011-01-13 MX MX2012008280A patent/MX341133B/en active IP Right Grant
- 2011-01-13 EP EP11733353.4A patent/EP2533783B8/en active Active
- 2011-01-13 BR BR112012017441-0A patent/BR112012017441B1/en active IP Right Grant
- 2011-01-13 KR KR1020127021121A patent/KR101781663B1/en active IP Right Grant
- 2011-01-13 US US13/522,044 patent/US8901156B2/en active Active
- 2011-01-13 EA EA201290638A patent/EA022964B1/en not_active IP Right Cessation
- 2011-01-13 JP JP2012549064A patent/JP6017313B2/en active Active
- 2011-01-13 AU AU2011205283A patent/AU2011205283B2/en active Active
- 2011-01-13 SG SG2012050076A patent/SG182401A1/en unknown
- 2011-01-13 ES ES11733353.4T patent/ES2560627T3/en active Active
- 2011-01-13 CN CN201180013827.0A patent/CN103221047B/en active IP Right Grant
- 2011-01-13 CA CA2787018A patent/CA2787018A1/en not_active Abandoned
- 2011-01-13 WO PCT/US2011/021089 patent/WO2011088181A1/en active Application Filing
-
2012
- 2012-07-10 ZA ZA2012/05125A patent/ZA201205125B/en unknown
- 2012-07-12 IL IL220939A patent/IL220939A/en active IP Right Grant
-
2014
- 2014-10-22 US US14/520,633 patent/US20150038534A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX341133B (en) | 2016-08-08 |
EP2533783B8 (en) | 2015-12-16 |
CN103221047B (en) | 2014-12-17 |
EA022964B1 (en) | 2016-03-31 |
ZA201205125B (en) | 2013-03-27 |
KR101781663B1 (en) | 2017-09-25 |
EP2533783B1 (en) | 2015-11-04 |
WO2011088181A1 (en) | 2011-07-21 |
AU2011205283A1 (en) | 2012-08-02 |
US20130059883A1 (en) | 2013-03-07 |
ES2560627T3 (en) | 2016-02-22 |
US20150038534A1 (en) | 2015-02-05 |
BR112012017441A2 (en) | 2016-04-19 |
EP2533783A1 (en) | 2012-12-19 |
KR20130036093A (en) | 2013-04-10 |
CN103221047A (en) | 2013-07-24 |
IL220939A (en) | 2016-11-30 |
MX2012008280A (en) | 2012-11-23 |
WO2011088181A9 (en) | 2013-01-31 |
EA201290638A1 (en) | 2013-02-28 |
US8901156B2 (en) | 2014-12-02 |
JP6017313B2 (en) | 2016-10-26 |
SG182401A1 (en) | 2012-08-30 |
AU2011205283B2 (en) | 2014-07-10 |
EP2533783A4 (en) | 2013-07-17 |
CA2787018A1 (en) | 2011-07-21 |
BR112012017441B1 (en) | 2019-11-19 |
JP2013517278A (en) | 2013-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190135T1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
HRP20181800T1 (en) | Well | |
HRP20170903T1 (en) | Substituted pyrrolidine-2-carboxamides | |
IL249669D0 (en) | Substituted 5-fluoro-1h-pyrazolopyridines and use thereof | |
HRP20161308T1 (en) | 5-alkynyl-pyrimidines | |
HRP20160360T1 (en) | Substituted imidazopyridazines | |
HK1206004A1 (en) | Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3- | |
HRP20160094T1 (en) | Triazine-oxadiazoles | |
IL222176A (en) | Radioprotector compounds and methods | |
HK1178149A1 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4--- | |
ZA201207727B (en) | Morpholinylquinazolines | |
EP2547244A4 (en) | Combination juicer-blender | |
EP2736330A4 (en) | Compounds and methods | |
HK1179966A1 (en) | Tetrahydro-pyrido-pyrimidine derivatives -- | |
EP2566479A4 (en) | Azaindazoles | |
GB201215746D0 (en) | Rotocraft | |
HK1181747A1 (en) | 1-hydroxyimino-3-phenyl-propanes 1--3-- | |
EP2640189A4 (en) | 3-deutero-pomalidomide | |
GB201108084D0 (en) | Subbuffer objects | |
GB201205984D0 (en) | No details | |
GB201001833D0 (en) | Method | |
IL220939D0 (en) | Compounds and methods | |
HK1176934A1 (en) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes --[e] | |
GB201010196D0 (en) | Methods | |
EP2747560A4 (en) | Compounds and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |